Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026
Tenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial of TNX-103 in Patients with PH-HFpEF
Tenax Therapeutics Announces Late-Breaking Presentation of LEVEL Clinical Trial Data at ESC Congress 2026
Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
QIMC Identifies Three Fault-Controlled Helium Zones at New Salem-Apple River, Nova Scotia, and Expands Seismic Program to Approximately 50 Line-Kilometres
Flow Metals Identifies Widespread Epithermal Alteration and District-scale Structural Controls at Sixtymile
